Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

by Spencer, Andrew, Samoilova, Olga, Chng, Wee-Joo, Labotka, Richard, Li, Cong, Wu, Kwang-Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral
Published 2023

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

by Goldschmidt, Hartmut, Dimopoulos, Meletios A, Rajkumar, S Vincent, Weisel, Katja C, Moreau, Philippe, Chng, Wee-Joo, Mikala, Gabor, Cavo, Michele, Ramasamy, Karthik, Suryanarayan, Kaveri, Teng, Zhaoyang, Labotka, Richard, Victoria Mateos, Maria
Published 2022

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

by Dimopoulos, Meletios A, Spicka, Ivan, Quach, Hang, Oriol, Albert, Hajek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, Maria-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Published 2022